Transgene Biotek will sell one of its bio-generic products 'Erythropoietin', to Tss Export GmbH for a total consideration of $5 million (over Rs 26 crore). The management of Transgene has formalised the sale of technology of one of its bio-generic products, Erythropoietin to 'Tss Export GmbH FZE' for a total consideration of $5 million.

Erythropoietin is a hormone produced by the kidney that promotes the formation of red blood cells in the bone marrow. This sale of technology is expected to be completed during a period of approximately 5-6 months. With the market for Erythropoietin set to become very competitive, the management of Transgene has decided to monetise some of the dormant technologies through either out-licensing or strategic partnerships within and outside India. The company had earlier out-licensed two of its technologies - a recombinant Hepatitis B Vaccine to one of the largest vaccine producers in the world, and more recently Orlistat to one of the biggest Indian pharma companies with a significant presence on the global arena.

Transgene Biotek Share Price

2.84 0.21 (7.98%)
06-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 399.15
Indegene 459.35
CMS Info Systems 300.35
JITF Infralogistics 355.50
Sagility 39.22
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×